2C8Y image
Deposition Date 2005-12-08
Release Date 2006-07-04
Last Version Date 2024-11-13
Entry Detail
PDB ID:
2C8Y
Title:
thrombin inhibitors
Biological Source:
Source Organism:
HOMO SAPIENS (Taxon ID: 9606)
HIRUDO MEDICINALIS (Taxon ID: 6421)
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.25
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
C 1 2 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:THROMBIN LIGHT CHAIN
Gene (Uniprot):F2
Chain IDs:A
Chain Length:36
Number of Molecules:1
Biological Source:HOMO SAPIENS
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:THROMBIN HEAVY CHAIN
Gene (Uniprot):F2
Chain IDs:B
Chain Length:259
Number of Molecules:1
Biological Source:HOMO SAPIENS
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:HIRUDIN VARIANT-2
Chain IDs:C (auth: I)
Chain Length:12
Number of Molecules:1
Biological Source:HIRUDO MEDICINALIS
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
TYS C TYR O-SULFO-L-TYROSINE
Primary Citation
Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors
J.Med.Chem. 49 1346 ? (2006)
PMID: 16480269 DOI: 10.1021/JM050850V

Abstact

The screening of fragments is an alternative approach to high-throughput screening for the identification of leads for therapeutic targets. Fragment hits have been discovered using X-ray crystallographic screening of protein crystals of the serine protease enzyme thrombin. The fragment library was designed to avoid any well-precedented, strongly basic functionality. Screening hits included a novel ligand (3), which binds exclusively to the S2-S4 pocket, in addition to smaller fragments which bind to the S1 pocket. The structure of these protein-ligand complexes are presented. A chemistry strategy to link two such fragments together and to synthesize larger drug-sized compounds resulted in the efficient identification of hybrid inhibitors with nanomolar potency (e.g., 7, IC50 = 3.7 nM). These potent ligands occupy the same area of the active site as previously described peptidic inhibitors, while having very different chemical architecture.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback